Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 9/20 | 0.67 |
| ▸ | LMNA | P02545 | 3/20 | 0.64 |
| ▸ | MAPT | P10636 | 3/20 | 0.64 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.54 |
| ▸ | SLC6A5 | Q9Y345 | 4/20 | 0.51 |
| ▸ | SLC6A9 | P48067 | 3/20 | 0.51 |
| ▸ | MEN1 | O00255 | 2/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.50 |
| ▸ | HPGD | P15428 | 1/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.50 |
| ▸ | IDE | P14735 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24993657 | 0.90 | ALDH1A1 (0.68) | ALDH1A1LMNAMAPTSMN1; SMN2SLC6A5 | |
| SCHEMBL28923676 | 0.89 | ALDH1A1 (0.67) | ALDH1A1LMNAMAPTSMN1; SMN2SLC6A5 | |
| SCHEMBL25403643 | 0.87 | ALDH1A1 (0.64) | ALDH1A1LMNAMAPTSMN1; SMN2SLC6A5 | |
| SCHEMBL29803356 | 0.84 | ALDH1A1 (0.67) | ALDH1A1LMNAMAPTSMN1; SMN2SLC6A5 | |
| SCHEMBL6808636 | 0.84 | ALDH1A1 (0.67) | ALDH1A1LMNAMAPTSMN1; SMN2SLC6A5 | |
| SCHEMBL1810972 | 0.84 | ALDH1A1 (0.70) | ALDH1A1LMNAMAPTSMN1; SMN2SLC6A5 | |
| SCHEMBL29803658 | 0.84 | ALDH1A1 (0.70) | ALDH1A1LMNAMAPTSMN1; SMN2SLC6A5 | |
| SCHEMBL25404908 | 0.84 | ALDH1A1 (0.70) | ALDH1A1LMNAMAPTSMN1; SMN2MEN1 | |
| SCHEMBL31639389 | 0.84 | ALDH1A1 (0.70) | ALDH1A1LMNAMAPTSMN1; SMN2MEN1 | |
| SCHEMBL2531674 | 0.84 | ALDH1A1 (0.70) | ALDH1A1LMNAMAPTSMN1; SMN2MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1951684-B1 | BI-ARYL META-PYRIMIDINE INHIBITORS OF KINASES | TARGEGEN INC (US) | 2016-07-13 | — | — | EP | disclosed |
| US-8604042-B2 | Bi-aryl meta-pyrimidine inhibitors of kinases | TARGEGEN, INC. (US) | 2013-12-10 | — | — | US | disclosed |
| US-8138199-B2 | Use of bi-aryl meta-pyrimidine inhibitors of kinases | TARGEGEN, INC. (US) | 2012-03-20 | — | — | US | disclosed |
| US-8133900-B2 | Use of bi-aryl meta-pyrimidine inhibitors of kinases | TARGEGEN, INC. (US) | 2012-03-13 | — | — | US | disclosed |
| US-20110212077-A1 | BI-ARYL META-PYRIMIDINE INHIBITORS OF KINASES | TARGEGEN, INC. (US) | 2011-09-01 | — | — | US | disclosed |
| US-7825246-B2 | Bi-aryl meta-pyrimidine inhibitors of kinases | TARGEGEN, INC. (US) | 2010-11-02 | — | — | US | disclosed |
| US-20090286789-A1 | Bi-Aryl Meta-Pyrimidine Inhibitors of Kinases | TARGEGEN, INC. (US) | 2009-11-19 | — | — | US | disclosed |
| US-20090275582-A1 | Bi-Aryl Meta-Pyrimidine Inhibitors of Kinases | IMPACT BIOMEDICINES, INC. | 2009-11-05 | — | — | US | disclosed |
| US-7528143-B2 | Bi-aryl meta-pyrimidine inhibitors of kinases | TARGEGEN, INC. (US) | 2009-05-05 | — | — | US | disclosed |
| EP-1951684-A1 | BI-ARYL META-PYRIMIDINE INHIBITORS OF KINASES | Targegen, Inc. (US) | 2008-08-06 | — | — | EP | disclosed |
| US-20070259904-A1 | Bi-aryl meta-pyrimidine inhibitors of kinases | TARGEGEN, INC. (US) | 2007-11-08 | — | — | US | disclosed |
| US-20070191405-A1 | Bi-aryl meta-pyrimidine inhibitors of kinases | TARGEGEN, INC. (US) | 2007-08-16 | — | — | US | disclosed |
| WO-2007053452-A1 | BI-ARYL META-PYRIMIDINE INHIBITORS OF KINASES | TARGEGEN, INC. (US) | 2007-05-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090286789-A1 | Bi-Aryl Meta-Pyrimidine Inhibitors of Kinases | JAK2, TYK2, LTK | ALDH1A1 3662/4885LMNA 4525/4885MAPT 4206/4885 |
| US-20070191405-A1 | Bi-aryl meta-pyrimidine inhibitors of kinases | JAK2, TYK2, JAK3 | ALDH1A1 3235/4885LMNA 4817/4885MAPT 3127/4885 |
| US-20070259904-A1 | Bi-aryl meta-pyrimidine inhibitors of kinases | JAK2, TYK2, JAK3 | ALDH1A1 3235/4885LMNA 4817/4885MAPT 3127/4885 |
| US-20090275582-A1 | Bi-Aryl Meta-Pyrimidine Inhibitors of Kinases | JAK2, TYK2, JAK3 | ALDH1A1 3235/4885LMNA 4817/4885MAPT 3127/4885 |
| US-20110212077-A1 | BI-ARYL META-PYRIMIDINE INHIBITORS OF KINASES | JAK2, TYK2, JAK3 | ALDH1A1 3235/4885LMNA 4817/4885MAPT 3127/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.